When Pfizer Inc and BioNTech SE’s Covid-19 vaccine rolls off production lines, Shanghai Fosun Pharmaceutical Group Co. will be waiting to distribute it through a complex and costly system of deep-freeze airport warehouses, refrigerated vehicles and inoculation points across China. After they reach vaccination centers, the shots must be thawed from -70 degrees celsius and injected within five days, if not they go bad. Then the herculean journey from warehouse freezer to rolled-up sleeve must be undertaken all over again - to deliver the second booster shot a month later. The roadmap sketched out by the company, which has licensed the vaccine for Greater China, offers a glimpse into the enormous and daunting logistical challenges faced by those looking to deliver Pfizer’s experimental vaccine after it showed ‘extraordinary’ early results from final stage trials, raising hopes of a potential end to the nearly year-long pandemic. That euphoria is now being diluted by the realization that no currently used vaccine has ever been made from the messenger RNA technology deployed in Pfizer’s shot, which instructs the human body to produce proteins that then develop protective antibodies. That means that countries will need to build from scratch the deep-freeze production, storage and transportation networks needed for the vaccine to survive. The massive investment and coordination required all but ensures that only rich nations are guaranteed access - and even then perhaps only their urban populations.